2-DG Concentration and Duration for Glycolysis Inhibition

Useful inhibitor, poor glycolysis-specific control at high doses.

Mechanism, and Where It Leaks

2-DG is transported by glucose transporters, phosphorylated by hexokinase, and not further metabolised, so it accumulates as 2-DG-6-phosphate and competitively inhibits glucose phosphorylation.

EffectMechanismRelevance
Glycolytic inhibitionCompetition at hexokinase; G6P depletionThe intended effect
Glycosylation inhibition2-DG-6-phosphate competes in the hexosamine pathwayInduces ER stress and UPR at effective doses
G6P depletionLoss of the PPP substrateReduces NADPH and nucleotide synthesis
Growth arrestLoss of biosynthetic precursorsConfounds viability interpretation
Insulin-independent uptake modulationTransporter regulationCell-type dependent

Important distinction. The intracellular 2-DG-6-phosphate concentration, not the medium concentration, determines the effect, and it depends on transporter expression and on the glucose concentration in the medium. A 10 mM dose in low glucose is not the same experiment as 10 mM in high glucose.

Part 1 — Concentration Ranges

ConcentrationTypical contextExpected effectCaveat
1–5 mMSensitisation; tracer-adjacent usePartial inhibitionSmall effect; hard to resolve
10–25 mMStandard glycolysis blockadeSubstantial inhibition within 30–60 minGlycosylation effects begin
50 mMSeahorse injection; strong blockadeNear-complete inhibitionER stress within the assay window
>50 mMRarely justifiedSaturation of the transporterOsmotic and toxicity effects

The third row is the standard for a plate-based inhibition step, and it is at the upper end of what a mechanism claim should use. For a 24-hour treatment intended to test dependence, 10–25 mM with a viability control is usually more interpretable than 50 mM.

Part 2 — Duration and Kinetics

WindowWhat happensDesign note
5–15 minG6P falls; glycolytic flux fallsSuitable for acute flux measurements
30–60 minMaximal biochemical effect; lactate release fallsSuitable for Seahorse and short flux assays
2–6 hGrowth arrest begins; ATP may fall if OXPHOS is limitedViability must be measured
24 hCell-cycle arrest; UPR; possible apoptosisThe effect is no longer glycolysis-specific

Readout note. At 24 hours, a 2-DG effect on a phenotype is compatible with glycolytic inhibition, with glycosylation inhibition, with ER stress, or with growth arrest. Isolating glycolysis requires a shorter window, or a rescue that restores the specific missing product.

Part 3 — Controls That Make the Claim Specific

ControlWhat it testsInterpretation
Mannose supplementationGlycosylation versus glycolysisMannose restores glycosylation without restoring glycolysis; rescue by mannose indicates a glycosylation mechanism
Glucose titrationCompetitive reversalReversal by excess glucose confirms hexokinase competition
Pyruvate or uridine supplementationDownstream product replacementDistinguishes ATP from biosynthetic precursor limitation
Viability and proliferationWhether the phenotype is deathEssential at any dose above 10 mM
Osmolarity controlNon-specific osmotic effectMatched osmolarity with an inert solute

The first control is the most informative and the least used. Mannose enters the hexosamine pathway without feeding glycolysis, so a phenotype reversed by mannose is more likely a glycosylation effect than a bioenergetic one.

Part 4 — Using 2-DG as a Seahorse Injection

In the glycolysis stress test, 2-DG is injected last to establish the non-glycolytic acidification baseline.

  • • Concentration: 50 mM final is conventional.
  • • Timing: allow two to three measurement cycles after injection for the effect to complete.
  • • Interpretation: the residual acidification is not zero, and includes respiratory and other contributions.
  • • Caveat: at this dose and over this window, ER stress may begin, so the residual rate is a lower bound rather than a true non-glycolytic baseline.

Part 5 — Common Failures

  • • Single high dose and a 24-hour endpoint, where the mechanism cannot be attributed.
  • • Glucose concentration unrecorded, although it determines the effective inhibition.
  • • No viability measurement, so growth arrest is reported as a metabolic effect.
  • • Mannose control omitted in a long treatment.
  • • 2-DG described as a glycolysis-specific inhibitor without qualification.
  • • Osmolarity unmatched at 50 mM, where the solute load is substantial.
  • • Injection artefact interpreted as a rate change in plate assays.

Part 6 — Where This Article Connects

This is the inhibitor counterpart to the pillar's dependence level: 2-DG is the fastest way to test whether a phenotype requires glycolysis, and the fastest way to produce an uninterpretable result if the window is too long. The Seahorse protocol article covers its use as an injection; the lactate article covers the alternative of measuring the product instead of inhibiting the pathway.

If you need glycolysis-dependence testing with mannose and pyruvate rescue controls, we can scope the design with you.

Contact EDITGENE to request a project consultation or quote.

Scientific scope and validation note

Effective concentrations and the balance between glycolytic and glycosylation effects vary by cell type, transporter expression and medium glucose; the ranges here are starting points.

Inhibition of a pathway does not establish that the pathway is required for a phenotype unless the window and the rescue controls exclude alternative mechanisms.

Scientific interpretation and experimental design

  • • Intracellular concentration drives the effect. Medium glucose matters.
  • • Short windows are specific; long windows are not.
  • • Mannose separates glycosylation from glycolysis.
  • • Glucose titration confirms competition.
  • • Measure viability above 10 mM.
  • • 50 mM is a solute load. Match osmolarity.

Selected references for further reading

  • • Wick AN, Drury DR, Nakada HI, Wolfe JB. Localization of the primary metabolic block produced by 2-deoxyglucose. Journal of Biological Chemistry. 1957;224:963–969.
  • • Kurtoglu M, et al. Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Molecular Cancer Therapeutics. 2007;6:3049–3058.
  • • TeSlaa T, Teitell MA. Techniques to monitor glycolysis. Methods in Enzymology. 2014;542:91–114.

Related Products

Product name Cat.No. Species Gene ID
PBRM1 Knockout A-549 Cell Line EDJ0001-K01 Human 55193 Details Get a Quote
YTHDC1 Knockout A-549 Cell Line EDC07652 Human 91746 Details Get a Quote
TP53 Knockout HCT 116 Cell Line EDC07854 Human 7157 Details Get a Quote
Sirt2 Knockout MH-S Cell Line EDJ-KQ78173 Mouse 64383 Details Get a Quote
TFE3 Knockout KGN Cell Line EDJ-KQ48 Human 7030 Details Get a Quote
Stub1 Knockout MB49 Cell Line EDJ-KQ53 Mouse 56424 Details Get a Quote
ARID1A Knockout SNK-6 Cell Line EDJ-KQ64 Human 8289 Details Get a Quote
Tet1 Knockout Kupffer Cell Line EDJ-KQ88 Mouse 52463 Details Get a Quote
NR1H3 Knockout HEK293T Cell Line EDJ-KQ109 Human 10062 Details Get a Quote
NR1H2 Knockout HEK293T Cell Line EDJ-KQ110 Human 7376 Details Get a Quote
RPS6KB2 Knockout HEK293 Cell Line EDJ-KQ125 Human 6199 Details Get a Quote
SMAD6 Knockout HEK293 Cell Line EDJ-KQ126 Human 4091 Details Get a Quote
JUN Knockout HEK293 Cell Line EDJ-KQ176 Human 3725 Details Get a Quote
JUN Knockout HEK293T Cell Line EDJ-KQ184 Human 3725 Details Get a Quote
ALKBH5 Knockout HEK293 Cell Line EDJ-KQ186 Human 54890 Details Get a Quote
Contact Us
*
*
*
How did you hear about us: